
Capital and financing are one the most important factors for facilitating product development and growth for a young life science company. As many start-ups have years of costly development ahead, they need to go hand in hand with investors for a long period before they can, hopefully, generate substantial revenues. One of the more important factors for life sciences development regions is thus a well-functioning venture capital market and the ability to attract and facilitate foreign investment.
Among the Nordic countries, the conditions for venture capital markets vary extensively, as well as their success in attracting foreign investors. In this section, we present companies representing the venture capital market in the Nordic countries and their views on their home markets. We also present their strategies for finding interesting objects and the effect the current crisis in the banking system has had on their business.
Related articles:
Karo Bio - the risk is too high
Promising Hepatitis drug may lift Medivir during the fall
Top three tiers - Q1 2010
Business deal of the quarter Q1 2010:
Medivir closes license agreement with Meda
Business deal of the quarter Q4 2009:
Biovitrum Swedish Orphan creates a strong platform for a new Swedish speciality pharma
Business deal of the quarter Q3 2009:
Orexo strikes deal with Novartis
Biobusiness: What's going on in the life science market?
Business deal of the quarter Q2 2009:
Q-Med closes deal with Oceana Therapeutics
Biobusiness: The Nordic Pharma Industry
Business deal of the quarter Q1 2009:
The financial crisis has not affected Getinge's appetite
Danish venture capitalists increase investments in the midst of the credit crunch
What makes the Nordic countries attractive to a venture capitalist?